246264-30-2Relevant academic research and scientific papers
Sulfonamide derivatives
-
Page column 115, (2010/02/05)
A compound of the formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: R1is H or NHOH. R2is H, optionally substituted alkyl, cycloalkyl or a group —AR6. A is an alkylene which may be optionally interrupted by O, —S(O)m— or —N(R9). R6is a group (II), (III), (IV) X is O, S, —N(R10)—, —C(R11)(R12)—. Y is O, CO, —S(O)n—, —N(R10)—, —C(R11)(R12)—. Each of R7and R8is H, alkyl, COOH, optionally substituted alkyl, etc. Each of R9, R10, R11, and R12is H, alkyl, etc. Each of m and n is 0 to 2. R3is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl. R4is optionally substituted (hetero)arylene. R5is optionally substituted alkyl, optionally substituted (hetero)aryl. These compounds have matrixmetalloproteinase—13 inhibitory activity and aglycanase inhibitory activity.
SULFONAMIDE DERIVATIVES
-
, (2008/06/13)
The object is to provide a compound having matrixmetalloproteinase-13 inhibitory activity and aglycanase inhibitory activity. A compound of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof:{R1: H, NHOH; R2: H, optionally substituted alkyl, cycloalkyl, a group -AR6 [A: an alkylene which may be optionally interrupted by O, -S(O)m- or -N(R9); R6: a group (II), (III), (IV)X: O, S, -N(R10)-, -C(R11)(R12)-; Y: O, CO, -S(O)n-, -N(R10)-, -C(R11)(R12)-; R7, R8: H, alkyl, COOH, optionally subsituted alkyl, etc.; R9, R10, R11,R12: H, alkyl, etc.; m, n: 0 to 2]R3: H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl; R4: optionally substituted (hetero)arylene; R5: optionally substituted alkyl, optionally substituted (hetero)aryl}.
